Diagnostic utility of plasma ptau217, ptau181, GFAP for Alzheimer disease in a heterogeneous younger onset dementia clinical cohort
Eratne, D.; Li, Q.-X.; Lewis, C.; Dang, C.; Kang, M.; Grewal, J.; Loi, S.; Walterfang, M.; Evans, A.; Malpas, C.; Pedrini, S.; Martins, R.; Chatterjee, P.; Zetterberg, H.; Blennow, K.; Berkovic, S. F.; Santillo, A. F.; Collins, S.; Masters, C. L.; Velakoulis, D.; The MiND Study Group,
Show abstract
ObjectiveWe investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (A{beta}42, A{beta}40), neurofilament light (NfL) to distinguish AD from non-AD conditions, in a heterogenous clinical cohort of younger people. MethodsPlasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other profiles (OtherAT). ResultsSeventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 OtherAT. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to OtherAT (3.67 vs 1.12pg/mL, 3.87 vs 1.79pg/mL, 189 vs 80pg/mL, respectively). ptau217 distinguished AD from OtherAT with 90% accuracy (88% specificity, 100% sensitivity) ConclusionsPlasma ptau217 has strong diagnostic utility to diagnose AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patients symptoms.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease 98%
- The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa 98%
- CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation 96%
Similar papers in this journal
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 96%
- Association of Item-Level Responses to Cognitive Function Index with Tau Pathology and Hippocampal volume in The A4 Study 96%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 96%
Similar papers in this journal
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort 98%
- Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease 97%
- The behavioral variant of Alzheimer’s disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex 96%
Similar papers in this journal
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 97%
- Identifying Proteomic Prognostic Markers for Alzheimer’s Disease with Survival Machine Learning: the Framingham Heart Study 95%
- Plasma brain-derived p-tau217 outperforms other p-tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden 94%